Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C

Inclusion Criteria: * HCV infection confirmed on a positive test for anti-HCV antibody and HCV RNA detectable in serum by Polymerase Chain Reaction. * Histological diagnosis of chronic hepatitis. * Patients who were non-responders to previous treatment with pegylated interferon and ribavirin or who had contraindicated the antiviral treatment. * Age between 18 and 65 years. * Ability to provide informed consent. * Absence of significant alcohol ingestion (weekly ethanol consumption of less than 40 g) Exclusion Criteria: * Presence of other form of liver diseases (viral or autoimmune hepatitis, drug-induced liver disease, nonalcoholic steatohepatitis, metabolic and hereditary liver disease and α-1 antitrypsin deficiency). * Pregnancy or lactation. * Decompensated cirrhosis. * Absence of clinical and ultrasonographic evidence of liver cancer, with α-fetoprotein levels ≤ 200 ng/ml. * Refusal to participate in the study. * Concomitant disease with reduced life expectancy. * Severe psychiatric conditions. * Drug dependence. * Co-infection with hepatitis A or B or HIV. * Pregnancy.